Understanding a New Treatment Option for HER2-Positive Gastric Cancer

This educational webinar provides an overview of HER2-positive gastric cancer, the role of biomarker testing in identifying eligible patients for targeted therapy, and emerging treatment advances that may help improve outcomes for those living with this disease.

During the webinar, participants hear from Samuel J. Klempner, MD, FASCO who discusses:

- The importance of HER2 biomarker testing in gastric cancer

- Current treatment approaches for HER2-positive disease

- New treatment options and clinical data

- Practical considerations for patients, caregivers, and healthcare teams

This webinar is intended to support awareness and education within the gastric cancer community and provide advocacy organizations, patient navigators, and other stakeholders with information they can share with the patients and families they serve.

Speaker:

Samuel J. Klempner, MD, FASCO

Program Director, Gastroesophageal Cancers

Tobins Family Endowed Chair in Esophagogastric Cancer Massachusetts General Hospital

Associate Professor, Harvard Medical School

Please note: This webinar is intended for educational and informational purposes only. It does not constitute medical advice, nor is it intended to recommend any specific treatment. Attendees should consult their healthcare providers regarding individual medical decisions.